Posts by Joseph Arbodela-Velasquez, MD, PhD
RUNX1 Inhibition Proposed for Prevention, Treatment of Lung Injury in Severe COVID-19
Leo Am Kim, MD, PhD, and Joseph F. Arboleda-Velasquez, MD, PhD, of Mass Eye and Ear, and colleagues found that a small-molecule inhibitor of the RUNX1 transcription factor robustly ameliorates lung fibrosis in an animal model and reduces expression of host proteins critical to SARS-CoV-2 infection.
Case of Resistance to Autosomal Dominant Alzheimer's Disease Suggests New Direction for Treatment
A woman with autosomal dominant Alzheimer's disease had very late onset of mild cognitive impairment, apparently because she was homozygous for the APOE3 Christchurch mutation.
Rare Mutation in Colombian Woman Reveals New Targets for Alzheimer's Research and Treatment
A Colombian woman remained cognitively healthy for decades longer than her family members who share the Alzheimer's-causing presenilin 1 mutation. Researchers from Massachusetts General Hospital reviewed her genome and discovered new potential therapeutic target opportunities for the disease.
Dr. Arboleda-Velasquez studies the cell signaling mechanisms that control the integrity of the vasculature in a diabetic environment. He uses novel technologies to study cell-cell and protein-protein interactions and uses imaging methods and enzymes to explore the cell signaling circuitry underlying diabetic microangiopathy. In addition, he is investigating novel mechanisms that contribute to proliferative diabetic retinopathy using patient-derived cell cultures and next-generation sequencing approaches. This research may lead to therapeutic approaches for diabetic retinopathy, which stands as the most prevalent cause of blindness in working adults.